“Woah! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $30/month

Get 2 Weeks Free

A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer

A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer IRN 80 mg/m 2 days 1, 8, 22, 29 in combination with capecitabine 1,500 mg/m 2 /day in divided dose days 2–15 and 23–36 has an acceptable toxicity profile and resulted in modulation of S-phase in 4/5 specimens examined. Further studies of the activity of this combination and modulatory effect of IRN are warranted. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals
Loading next page...
 
/lp/springer-journal/a-phase-i-study-of-capecitabine-and-a-modulatory-dose-of-irinotecan-in-txn3bkF8cP

You're reading a free preview. Subscribe to read the entire article.

And millions more from thousands of peer-reviewed journals, for just $30/month

Get 2 Weeks Free

To be the best researcher, you need access to the best research

  • With DeepDyve, you can stop worrying about how much articles cost, or if it's too much hassle to order — it's all at your fingertips. Your research is important and deserves the top content.
  • Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.
  • All the latest content is available, no embargo periods.

Stop missing out on the latest updates in your field

  • We’ll send you automatic email updates on the keywords and journals you tell us are most important to you.
  • There is a lot of content out there, so we help you sift through it and stay organized.